logo-loader
viewOpen Orphan PLC

Open Orphan inks software deal

The company will include Empiric’s privacy-preserving and artificial intelligence-enabled software in its rare disease database

Open Orphan Plc -
Orphan drugs treat rare diseases and address unmet medical needs

Open Orphan Plc (LON:ORPH) said it has taken an “exciting step” towards the completion of it Genomic Health Data Platform following a tie-up with a firm called Empiric Logic.

As part of the collaboration agreement Open Orphan will include Empiric’s privacy-preserving and artificial intelligence-enabled software in its rare disease database.

Open Orphan intends to “roll up” a number of orphan drug services businesses. It is currently developing the database and owns the Virtual Rep platform, which enables pharma companies to engage key opinion leaders and physicians.

In targeting the arena of orphan drugs, which treat rare diseases and address unmet medical needs, it is tapping into one of the fastest expanding sectors in the drugs industry.

Of the latest announcement, Open Orphan chief executive Cathal Friel said: "This is an exciting step towards the completion of our genomic Health Data platform, and we are delighted to have Empiric on board to help us quickly and securely become one of the largest databases of rare disease patients in Europe."

Quick facts: Open Orphan PLC

Price: 13.8 GBX

AIM:ORPH
Market: AIM
Market Cap: £81.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Innovenn split will ‘maximise shareholder value’, says Venn CEO

Venn Life Sciences Holdings plc (LON:VENN) chief executive Tony Richardson says that separating Innovenn from its core business simplifies the firm and generates more value for shareholders. Speaking exclusively to Proactive, Richardson says: “Spinning [Innovenn] out, we believe, will...

on 5/10/16

2 min read